Anti-hCD20-hIgG4 (S228P)

Engineered monoclonal human IgG4 antibody against human CD20

Anti-hCD20-hIgG4 (S228P) features the variable region of rituximab and a mutated constant region of the human IgG4 isotype reported to reduce Fab-arm exchange [1].

Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

Anti-hCD20-hIgG4 (S228P) is an engineered human IgG4 isotype. IgG4 antibodies display low antibody-dependent cell-mediated cytotoxicity (ADCC) and no complement-dependent cytotoxicity (CDC). IgG4s are dynamic molecules that exchange Fab arms by swapping a heavy chain and attached light chain (half molecule) with a heavy-light chain pair from another molecule, resulting in bispecific antibodies [1, 2]. IgG4 molecules thereby lose their ability to cross-link antigen and to form immune complexes under most conditions [2]. Thus, mutations that prevent Fab-arm exchange in vivo should be considered when designing therapeutic IgG4.

The constant region of Anti-hCD20-hIgG4 (S228P) contains the S228P mutation which reduces Fab-arm exchange by stabilizing the disulfides in the core-hinge of the IgG4 molecules [1].
Anti-hCD20-hIgG4 (S228P) was generated by recombinant DNA technology.
It has been produced in CHO cells and purified by affinity chromatography with protein G.


Clonality: Engineered monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgG4
Application :
Anti-hCD20-hIgG4 (S228P) can be compared with anti-hCD20-hIgG4 to study the impact of Fab-arm exchange.

Quality control
- The absence of bacterial contamination (e.g. endotoxins and peptidoglycans) is controlled using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
- The recognition of human CD20 with this antibody is tested using flow cytometry.


100 µg purified anti-hCD20-hIgG4 (S228P) antibody, provided azide-free and lyophilized.

Store lyophilized antibody at -20°C. Lyophilized product is stable for 1 year.


1. Labrijn AF. et al., 2009. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 27(8):767-71.
2. van der Neut Kolfschoten M. et al., 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 317(5844):1554-7.


Recent articles using InvivoGen Anti-hCD20-hIgG4 (S228P)


Anti-hCD20-hIgG4 (S228P)

Description Engineered monoclonal human IgG4 antibody against human CD20
Cat. Codehcd20-mab14
Unit Size100 µg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".